| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid J exerts its biological effects through multiple mechanisms. It suppresses LPS-induced NO and pro-inflammatory cytokine production in macrophages, with anti-inflammatory effects mediated via modulation of NF-κB or MAPK signaling pathways. As a triterpenoid, it may also interact with other cellular targets including membrane receptors, ion channels, and enzymes involved in inflammation and cancer progression. Its hepatoprotective effects involve protection against toxin-induced liver damage through antioxidant and anti-inflammatory mechanisms.
|
|---|---|
| ln Vitro |
In vitro, Ganoderic acid J suppresses LPS-induced NO and pro-inflammatory cytokine production in macrophages. Its anti-inflammatory effects are mediated via modulation of NF-κB or MAPK signaling pathways. The compound has also demonstrated anticancer activity by inhibiting tumor cell proliferation in various cancer cell lines. Its hepatoprotective effects have been characterized in liver cell models, where it protects against toxin-induced damage. The compound's activity is concentration-dependent, with effects observed at micromolar concentrations.
|
| ln Vivo |
In vivo, Ganoderic acid J has been studied for its anti-inflammatory, hepatoprotective, and anticancer activities. In animal models of inflammation, the compound reduces inflammatory cytokine production and tissue damage. Its hepatoprotective effects have been demonstrated in models of liver injury, where it protects against toxin-induced liver damage. The compound's anticancer activity has been evaluated in tumor models, showing inhibition of tumor growth. However, detailed in vivo data are limited.
|
| Enzyme Assay |
Non-cell-based assays for Ganoderic acid J involve characterization of its chemical properties and biological activities. The compound's structure is confirmed by NMR and MS. Its anti-inflammatory activity is measured by inhibition of NF-κB or MAPK signaling in cell-free systems. Antioxidant activity is assessed by DPPH radical scavenging assays. The compound's purity and stability are characterized by HPLC. Enzyme inhibition assays may be used to study its effects on specific targets involved in inflammation or cancer.
|
| Cell Assay |
Cellular assays for Ganoderic acid J are performed using macrophages (e.g., RAW 264.7) for anti-inflammatory studies and various cancer cell lines for anticancer studies. Cells are treated with Ganoderic acid J at various concentrations, and cellular responses are measured. NO production is measured by Griess assay. Pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6) is quantified by ELISA. NF-κB activation is evaluated by measuring NF-κB p65 nuclear translocation and IκB degradation. MAPK signaling (ERK, JNK, p38) is assessed by Western blot. Cell viability is measured by MTT assays. Apoptosis is assessed by Annexin V/PI staining.
|
| Animal Protocol |
In vivo experiments with Ganoderic acid J are conducted in animal models of inflammation, liver injury, or cancer. In inflammation models, animals are treated with Ganoderic acid J and challenged with LPS or other inflammatory stimuli. Inflammatory cytokine levels, tissue histology, and disease scores are measured. In liver injury models, animals are treated with hepatotoxins (e.g., CCl₄) and Ganoderic acid J, and liver enzymes, histology, and oxidative stress markers are assessed. In cancer models, tumor growth inhibition is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ganoderic acid J have not been extensively characterized. As a triterpenoid, the compound is expected to have moderate lipophilicity and may be absorbed after oral administration. Its bioavailability, half-life, metabolism, and excretion are not well-defined. The compound's stability in biological matrices and its metabolic fate are areas of ongoing research. Comprehensive PK studies are needed to support further development.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Ganoderic acid J has not been comprehensively evaluated. As a natural product from Ganoderma lucidum, which has a long history of safe use as a medicinal mushroom, the compound is generally considered to have low toxicity. However, comprehensive toxicological studies including genotoxicity, organ toxicity, and maximum tolerated dose have not been fully characterized. The compound is for research use only and is not intended for human consumption.
|
| References | |
| Additional Infomation |
Ganoderic acid J (CAS# 100440-26-4) is a natural terpenoid (lanostane-type triterpene) isolated from Ganoderma lucidum with the molecular formula C₃₀H₄₂O₇ and a molecular weight of 514.65. It is also known as ganoderate J. The compound exhibits diverse biological activities including anti-inflammatory, hepatoprotective, and anticancer effects. Its anti-inflammatory effects are mediated via modulation of NF-κB or MAPK signaling pathways, suppressing LPS-induced NO and pro-inflammatory cytokine production in macrophages. Ganoderic acid J is available for research use only and is not approved as a therapeutic agent.
|
| Molecular Formula |
C30H42O7
|
|---|---|
| Molecular Weight |
514.65028
|
| Exact Mass |
514.293
|
| CAS # |
100440-26-4
|
| PubChem CID |
14109407
|
| Appearance |
Light yellow to green yellow solid
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KIJCKCLHIXLFEW-JJWHRAAESA-N
|
| InChi Code |
InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18,21,23,35H,8-14H2,1-7H3,(H,36,37)/t15-,16?,18-,21+,23+,28+,29-,30+/m1/s1
|
| Chemical Name |
(6R)-6-[(5R,10S,13R,14R,15S,17R)-15-hydroxy-4,4,10,13,14-pentamethyl-3,7,11-trioxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| Synonyms |
Ganoderic acid J
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (97.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL | |
| 5 mM | 0.3886 mL | 1.9431 mL | 3.8861 mL | |
| 10 mM | 0.1943 mL | 0.9715 mL | 1.9431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
